Activated protein C and hospital mortality in septic shock: A propensity-matched analysis

Critical Care Medicine

Volumn 38, Issue 4, 2010, Pages 1101-1107

  Lindenauer, Peter K ^a,b   Rothberg, Michael B ^a,b   Nathanson, Brian H ^c   Pekow, Penelope S ^a,d   Steingrub, Jay S ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OptiStatim LLC   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Critical care; Drug therapy; Outcome assessment; Retrospective studiesx; Sepsis; Shock

Indexed keywords

ADRENALIN; AMINOGLYCOSIDE; CEPHALOSPORIN DERIVATIVE; DOPAMINE; DROTRECOGIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; NORADRENALIN; PHENYLEPHRINE; QUINOLONE DERIVATIVE; THIAMINE; VANCOMYCIN; VASOPRESSIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY ARTERY; RACE DIFFERENCE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; STROKE; SURVIVAL; TRANSFUSION; UNITED STATES;

EID: 77950258792     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181d423b7     Document Type: Article

References (39)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Finfer S, Bellomo R, Lipman J, et al: Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units [erratum appears in Intensive Care Med 2004; 30:1252]. Intensive Care Med 2004; 30:589-596
3. Harrison DA, Welch CA, Eddleston JM: The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: Secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care (London) 2006; 10:R42
4. Karlsson S, Varpula M, Ruokonen E, et al: Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: The Finnsepsis study. Intensive Care Med 2007; 33:435-443
5. Linde-Zwirble WT, Angus DC: Severe sepsis epidemiology: Sampling, selection, and society. Crit Care 2004; 8:222-226
6. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
7. Abraham E, Laterre P-F, Garg R, et al: Dro-trecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 29:1332-1341
8. Bernard GR, Margolis BD, Shanies HM, et al: Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): A single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004; 125: 2206-2216
9. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
10. Vincent J-L, Bernard GR, Beale R, et al: Dro-trecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33:2266-2277
11. Finfer SRV, Thompson BT, Barie PS, et al: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008; 34:1935-1947
12. University of Versailles: Activated protein C and corticosteroids for human septic shock (APROCCHS). Available at http://clinicaltrials. gov/ct2/show/NCT00625209. Accessed January 26, 2010
13. Elixhauser A, Steiner C, Harris DR, et al: Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27
14. Quan H, Parsons GA, Ghali WA: Validity of information on comorbidity derived from ICD-9-Critical Care Medicine administrative data. Med Care 2002; 40:675-685
15. Vincent J-L, O'Brien J Jr, Wheeler A, et al: Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care (London) 2006; 10:R74
16. Wheeler A, Steingrub J, Schmidt GA, et al: A retrospective observational study of dro-trecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. Crit Care Med 2008; 36:14-23
17. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-2281
18. Kurth T, Walker AM, Glynn RJ, et al: Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163:262-270
19. Zhang J, Yu KF: What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280:1690-1691
20. Parsons L: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference. Cary, NC, SAS Institute, 2001
21. Lin DY, Psaty BM, Kronmal RA: Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998; 54:948-963
22. Nichol KL, Nordin JD, Nelson DB, et al: Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373-1381
23. Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepi-demiol Drug Safe 2007; 16:241-249
24. Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 16: 492-499
25. Warren HS, Suffredini AF, Eichacker PQ, et al: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030
26. Laterre P-F, Levy H, Clermont G, et al: Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004; 32:2207-2218
27. Eichacker PQ, Natanson C, Danner RL: Surviving sepsis-practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355:1640-1642
28. Friedrich JO, Adhikari NKJ, Meade MO: Dro-trecogin alfa (activated): Does current evidence support treatment for any patients with severe sepsis? Crit Care (London) 2006; 10:145
29. Gardlund B: Activated protein C (Xigris) treatment in sepsis: A drug in trouble. Acta Anaesthesiol Scand 2006; 50:907-910
30. Mackenzie AF: Activated protein C: Do more survive?. Intensive Care Med 2005; 31: 1624-1626
31. Annane D, Bellissant E, Cavaillon J-M: Septic shock. Lancet 2005; 365:63-78
32. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
33. Parrillo JE: Severe sepsis and therapy with activated protein C [erratum appears in N Engl J Med 2005; 353:2311]. N Engl J Med 2005; 353:1398-1400
34. Russell JA: Management of sepsis. [erratum appears in N Engl J Med 2006;355:2267.] N Engl J Med 2006; 355:1699-1713
35. Marti-Carvajal A, Salanti G, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database System Rev 2008; 1:D004388
36. Stukel TA, Fisher ES, Wennberg DE, et al: Analysis of observational studies in the presence of treatment selection bias: Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297: 278-285
37. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878-1886
38. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892
39. Ioannidis JP, Haidich AB, Pappa M, et al: Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286:821-830